Trial Profile
A Phase I/II Safety, Dose Finding and Feasibility Trial of MB-CART20.1 in Patients With Relapsed or Resistant CD20 Positive B-NHL
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs MB-CART20.1 (Primary)
- Indications B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Miltenyi Biotec GmbH
- 20 Sep 2021 Status changed from recruiting to active, no longer recruiting.
- 12 Feb 2019 Status changed from not yet recruiting to recruiting.
- 19 Sep 2018 New trial record